BCAT1 and neoplasm: Studies have shown that BCAT1 can resist cisplatin-induced cell death, and inhibiting the expression of BCAT1 can partially block the autophagy response of cancer cells, thereby regulating the sensitivity of cisplatin and reducing tumor drug resistance.